Patent cliff could create need for novel delivery tech

As blockbusters go off patent and generics companies scramble to compete, novel drug delivery tech could be the difference-maker in the marketplace, Labopharm's Shams Rustom said. Speaking at Interphex, Rustom said genericsmakers can get a leg up in the battle for off-patent profits by implementing new drug delivery methods to make a drug more convenient or bioavailable, in-PharmaTechnologist reports. With many big-time sellers losing their patents in the coming years, this could mean major opportunities for drug delivery firms, Rustom said. Report